BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Methods Development

Samsung Biologics to build Plant 5 for Bio Campus II expansion.

The company plans to begin construction in the first half of 2023 and commence operations in 2025 As part of Samsung Biologics' second Bio Campus, ...

March 17, 2023 | News

AtomVie Global Radiopharma builds industry-leading CDMO facility in Ontario.

Currently located on the McMaster University campus, AtomVie successfully operates a global leading Contract Development and Manufacturing Organi...

March 02, 2023 | News

SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center

The additional investment for the ‘R&PD Center’ was confirmed by the board of directors committee with a total of 261 million USD SK bio...

February 08, 2023 | News

Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market

Clinical development pipeline is essential to global business strategy Vetter Development Service offers comprehensive expertise for in-human trial mate...

February 02, 2023 | News

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization o...

January 11, 2023 | News

WuXi STA Launches First Continuous Manufacturing Line for Oral Solids

WuXi STA’s continuous manufacturing line features continuous direct compression equipment with unit operations including dispensing, blending, lubric...

January 04, 2023 | News

GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development

According to the collaboration agreements, WuXi XDC will actively promote GeneQuantum’s proprietary iLDC (intelligent Ligase-dependent Conjugation) a...

December 28, 2022 | News

WuXi STA Launches Another Parenteral Formulation Manufacturing Line at Wuxi city site

This new line features a fully automatic vial loading/unloading system and a built-in 15 m2 lyophilizer in a fully enclosed isolator. The filling line...

December 01, 2022 | News

WuXi AppTec Begins Construction of Wuxi STA Pharmaceutical East China R&D Facility

WuXi AppTec recently held the groundbreaking ceremony for its Wuxi STA Pharmaceutical East China R&D facility in tandem with the signing ceremony...

November 24, 2022 | News

CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth

New research from the CPHI Annual Report 2022 – launched during CPHI Frankfurt (1-3 November, 2022) – predicts that huge volumes of V...

October 28, 2022 | News

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft

GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft (Suk Chul Bae, CEO), a global research team led by Professor Suk Ch...

October 18, 2022 | News

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned Partial operations add fresh biomanufacturing capacity of 60,000...

October 12, 2022 | News

Merck Boosts Commercial Capacity in France as Part of New Millipore® CTDMO Services

New 2,700-square-meter facility expands production capacity for monoclonal antibodies (mAbs) and other recombinant proteins Clients benefit from differe...

October 05, 2022 | News

Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™

Two distinctive platforms will streamline the antibody development process. With an advanced design and high binding affinity, S-DUAL™ ensures opt...

September 30, 2022 | News

Stay Connected